The U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting on May 8, 2019 at the USPTO Headquarters in Alexandria, VA, and the Midwest Regional Office in Detroit, MI. The agenda for the meeting is as follows:
• Welcoming and Opening Remarks (9:00 - 9:20 am EDT) -- Damian Porcari, Director, Midwest Regional Office, and Andrew Wang, Gary Jones, and Daniel Sullivan, Directors, TC1600, USPTO
• TC quality action plan (9:20 - 9:50 am) -- Anne Gussow, QAS, TC1600, USPTO
• Antibody decisions and the written description requirement (9:50 - 10:30 am) -- Lora Driscoll, QAS, TC1600, USPTO
• Break (10:30 am - 10:40 am)
• Subject matter eligibility (35 U.S.C. § 101) - 2019 patent subject matter eligibility guidance (PEG) update (10:40 - 11:30 am) -- Marjorie Moran, SPE, TC1600, USPTO
• Lunch (11:30 am - 12:30 pm)
• Subject matter eligibility (101) outside perspectives (12:30 - 1:20 pm) -- Kathleen E. Chaffee, Patent Agent, Office of Technology Management, Washington University
• 101 discussion panel (1:20 - 2:50 pm) -- Andrew Wang, Director, TC1600 (moderator), Beverly A. Lyman, Chief Intellectual Property Counsel, Indiana University; Duane C. Marks, Patent Counsel, Bio-Products, Eli Lilly and Company; June Cohan, Senior Legal Advisor, OPLA; Marjorie Moran, SPE, TC1600
• Break (2:50 - 3:00 pm)
• Global Dossier (3:00 – 3:30 pm) -- Nelson Yang, Acting Director, IPBS, OIPC
• Cooperative Patent Classification (CPC) application in biotechnology (3:30 – 3:50 pm) -- Melenie Gordon, SPE, TC1600 and Sue Liu, SPE, TC1600
• Closing Remarks (3:50 - 4:00 pm) – Directors, TC1600, USPTO
Additional information regarding the BCP customer partnership meeting, including registration information for those wishing to attend the meeting or register for online participation, can be found here.
Comments